

Algorae Pharmaceuticals – Notice of AGM Proceedings

Melbourne, Australia, 6 September 2024: Algorae Pharmaceuticals Limited (Algorae or the Company) (ASX code: 1AI) advises that, in accordance with ASX Listing Rule 3.13.1 and clause 7 of the Company's Constitution, the next Annual General Meeting (AGM) of the Company is scheduled to be held at 11:00 am (AEDT) on Friday, 25 October 2024.

The closing date for the receipt of nominations from persons wishing to be considered for election as a director is 13 September 2024. Any nominations must be received in writing no later than 5.00pm (AEDT) on 13 September 2024 at the Company's registered office.

Full details of the agenda for the AGM, including details of how shareholders can participate in the Meeting, will be contained in the Notice of AGM, which will also contain a proxy form. The Notice of AGM will be sent to shareholders and a copy released on the ASX Market Announcements Platform and on the Company's website in due course.

This announcement has been approved by the Board of Directors of Algorae Pharmaceuticals Limited.

End

For more information, please visit www.algoraepharma.com

Corporate and Media Enquiries

Mr Brad Dilkes - Director

P: +61 422 180 317

E: brad@algoraepharma.com

About Algorae Pharmaceuticals

Algorae is a pharmaceutical development company focussed on addressing unmet medical needs through the discovery and development of novel treatments. The Company has assembled a proficient R&D team and established collaborations with reputable academic institutions to advance its promising drug candidates, which include AI-116 for the treatment of neurodegenerative disorders and/or dementia, AI-168 for cardiovascular disease and NTCELL for Parkinson's disease.

Algorae intends to expand its therapeutic pipeline using a proprietary artificial intelligence (AI) drug discovery and development platform. Known as Algorae Operating System (AlgoraeOS), the AI platform leverages extensive medical and scientific databases from various disciplines within an advanced system at the intersection of AI and pharmaceutical research. By employing machine learning, deep learning, and neural networks, the aim of AlgoraeOS is to uncover synergistic drug combinations that lead to the development of novel and effective treatments for any medical condition, aligning with Algorae's commitment to address unmet medical needs. Algorae is listed and publicly traded on the Australian Stock Exchange (ASX: 1AI), providing investors an opportunity to participate in the Company's growth.